The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...